Cleerly

At a glance

Pricing

Enterprise (per-study).

HIPAA

Not disclosed

SOC 2

Not disclosed

EHRs

—

Founded

—

HQ

US

Bottom line

AI-driven CCTA plaque quantification + CAD staging.

Free tier available.

Overview

Pricing

What it costs

Free tier only; no paid plans publicly disclosed.

Source: vendor pricing page. Verified May 23, 2026.

Peer-reviewed coverage

What the literature says

5 peer-reviewed studies indexed on PubMed evaluate Cleerly in clinical contexts. The most relevant are shown below, ranked by editorial relevance score combining title match, study design, recency, and journal tier.

Assessment of atherosclerotic plaque burden: comparison of AI-QCT versus SIS, CAC, visual and CAD-RADS stenosis categories.

Khan H, Bansal K, Griffin WF, et al.· Int J Cardiovasc Imaging· 2024Observational

This study assesses the agreement of Artificial Intelligence-Quantitative Computed Tomography (AI-QCT) with qualitative approaches to atherosclerotic disease burden codified in the multisociety 2022 CAD-RADS 2.0 Expert Consensus. 105 patients who underwent cardiac computed tomography angiography (CCTA) for chest pain were evaluated by a blinded core laboratory through FDA-cleared software (Cleerly, Denver, CO) that performs AI-QCT through artificial intelligence, analyzing factors such as % stenosis, plaque volume, and plaque composition. AI-QCT plaque volume was then staged by recently valid…

Using AI-Quantitative CT to evaluate the relationship between coronary artery calcium and segment involvement scores in quantifying coronary plaque burden.

Khan NA, Wesbey III G, Cobb G, et al.· Int J Cardiovasc Imaging· 2026

Accurate assessment of coronary plaque burden is essential for risk stratification in coronary artery disease (CAD). The Coronary Artery Disease – Reporting and Data System (CAD-RADS) 2.0 classification incorporates P-scores derived from coronary artery calcium (CAC) and segment involvement scores (SIS) to semi-quantitatively characterize plaque burden. However, limited data exist on the concordance and clinical implications of these two plaque characteristics. We retrospectively analyzed 461 coronary CT angiography (CCTA) studies using a commercial AI-based quantitative CT (AI-QCT) pl…

Increased high-risk plaque burden in type 2 diabetes: a 10-year follow-up study.

Gaillard EL, Cramer SHM, Hanssen NMJ, et al.· Cardiovasc Diabetol· 2025

Using serial coronary CT angiography (CCTA) imaging, we aimed to characterize baseline coronary plaque characteristics and quantify 10-year coronary plaque progression, including high-risk and low-density plaque presence, in patients with and without type 2 diabetes. A total of 299 patients underwent CCTA with a median scan interval of 10.2 [IQR 8.7-11.2] years. Patients who underwent coronary artery bypass grafting and vessels revascularized by percutaneous coronary intervention were excluded (n = 32). Scans were analyzed using atherosclerosis imaging-quantitative CCTA analysis…

The impact of lipoprotein(a) on coronary atherosclerotic plaque phenotype in primary prevention.

Verpalen VA, Coerkamp CF, Malkasian S, et al.· Eur J Prev Cardiol· 2026

Lipoprotein(a) (Lp[a]) is a causal risk factor for cardiovascular events. However, the effect of Lp(a) on coronary plaque composition and high-risk plaque (HRP) features has not been fully characterized. This study aimed to investigate the association between Lp(a) and coronary atherosclerotic plaque phenotype at the plaque level. This study included 710 patients who underwent coronary computed tomography angiography (CCTA) and had Lp(a) measured between 2008 and 2024. CCTA scans were analyzed with a previously validated artificial intelligence-based algorithm (AI-QCT, Cleerly Inc.). The asso…

NATURal history of coronary PlaquE on cardiac computed tomography in individuals without MACE or lipid-lowering therapy: NATURE-CTstudy.

Aldana-Bitar J, Krishnan S, Ichikawa K, et al.· J Cardiovasc Comput Tomogr· 2026

Coronary artery disease (CAD) progression has been examined mainly in cohorts enriched for major adverse cardiovascular events (MACE), a high burden of traditional risk factors, or prior exposure to risk-modifying therapies. In contrast, plaque progression is poorly described in patients without prior MACE and receiving no anti-atherosclerotic treatment who undergo cardiac computed tomography angiography (CCTA) for clinical indications. We therefore investigated atherosclerosis progression in this understudied population using serial CCTA. The NATURE-CT study retrospectively identified 205 pa…

See all on PubMed